Lisanti Capital Growth LLC Acquires 132,970 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

Lisanti Capital Growth LLC raised its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 75.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 308,440 shares of the biotechnology company's stock after purchasing an additional 132,970 shares during the quarter. ADMA Biologics accounts for approximately 1.8% of Lisanti Capital Growth LLC's investment portfolio, making the stock its 9th largest holding. Lisanti Capital Growth LLC owned approximately 0.13% of ADMA Biologics worth $6,119,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of ADMA. Raymond James Financial Inc. acquired a new position in ADMA Biologics during the 4th quarter valued at about $19,076,000. JPMorgan Chase & Co. boosted its position in ADMA Biologics by 272.5% in the fourth quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company's stock valued at $13,159,000 after buying an additional 561,310 shares during the last quarter. Victory Capital Management Inc. increased its holdings in ADMA Biologics by 52.8% in the 4th quarter. Victory Capital Management Inc. now owns 109,948 shares of the biotechnology company's stock worth $1,886,000 after buying an additional 38,002 shares during the period. Sei Investments Co. lifted its position in ADMA Biologics by 147.2% during the fourth quarter. Sei Investments Co. now owns 527,272 shares of the biotechnology company's stock valued at $9,043,000 after purchasing an additional 314,013 shares during the period. Finally, Swiss National Bank boosted its holdings in ADMA Biologics by 6.6% in the fourth quarter. Swiss National Bank now owns 458,400 shares of the biotechnology company's stock valued at $7,862,000 after purchasing an additional 28,500 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Up 0.3%

NASDAQ ADMA traded up $0.05 on Monday, hitting $18.21. 4,647,159 shares of the stock were exchanged, compared to its average volume of 3,251,516. The company has a market cap of $4.35 billion, a PE ratio of 32.43 and a beta of 0.47. The company has a 50-day moving average price of $20.54 and a 200-day moving average price of $18.74. ADMA Biologics Inc has a fifty-two week low of $10.21 and a fifty-two week high of $31.50. The company has a quick ratio of 3.36, a current ratio of 6.58 and a debt-to-equity ratio of 0.22.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.02). The company had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The company's quarterly revenue was up 40.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.08 EPS. Sell-side analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Insider Activity at ADMA Biologics

In other news, Director Jerrold B. Grossman sold 10,000 shares of the firm's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the sale, the director owned 478,194 shares in the company, valued at approximately $10,190,314.14. This trade represents a 2.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Steve Elms sold 194,749 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the transaction, the director directly owned 87,330 shares of the company's stock, valued at $1,767,559.20. This represents a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 464,621 shares of company stock worth $9,644,269 in the last quarter. Company insiders own 3.70% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ADMA. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Finally, Raymond James Financial boosted their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.